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Abstract
Ten years ago, one of the first papers published in Trials was a commentary entitled “Whose data set is it anyway?”
The commentary pointed out that trialists routinely refused requests for data sharing and argued that this attitude
was a community standard that had no rational basis. At the time, there had been few calls for clinical trial data
sharing and certainly no institutional support. Today the situation could not be more different. Numerous
organizations now recommend or require raw data to be made available, including the International Committee of
Medical Journal Editors, which recently proposed that clinical trial data sharing be a “condition of … publication.”
Furthermore, the literature is replete with papers covering an enormously wide variety of topics on data sharing.
But despite a tectonic shift in attitudes, we are yet to see clinical trial data sharing become an unquestioned norm,
where a researcher can readily download a data set from a trial almost as easily as they can now download a copy
of the published paper. The battle over the next few years is to go beyond changing minds to ensuring that real
data sets are routinely made available.
Background
It is often said that people don’t change. Indeed, it is
almost a point of academic pride to be cynical about our
capacity for change, and to view optimists as naïve and
callow. Yet change often happens remarkably quickly. In
2004, President George W Bush used opposition to gay
marriage to motivate his supporters; in 2015, the Supreme
Court legalized gay marriage with the majority support of
the American public. In 1988, Jesse Jackson's run for
president was considered a token exercise, leading News-
week magazine to ask: “What makes Jesse run?”; 2008 saw
the election of Barack Obama
I think we have seen similarly rapid change in terms of
attitudes to data sharing. Ten years ago, one of the first
papers published in Trials was a commentary entitled
“Whose data set is it anyway?” [1]. The commentary
pointed out that trialists tended to see trial data as their
personal property and would routinely refuse requests for
data sharing. As just one example, a National Institutes of
Health (NIH) investigator refused to release data from the
control group of a published trial, requested to help the
sample size calculation for a new study. Anecdotes were
complemented by survey data showing that three quarters
of trialists, as well as pharmaceutical industry groups,
were opposed to making raw data available after trial
publication.
The key argument of the commentary was that this atti-
tude was a community standard that had no rational basis.
Arguments against data sharing were entirely trivial, such
as spurious concerns about patient confidentiality – in
most cases, it is straightforward to deidentify a data set –
or complaints about the time and effort an investigator
would have to invest in making a data set ready for shar-
ing (would they not already have had to do so in order to
analyze the data for publication?). Moreover, other disci-
plines, from genomic researchers to economists, routinely
made data freely available. The clinical trialists did not
share data because that is not what clinical trialists did, a
social norm not much different in form from attitudes to-
wards gays and blacks.
At the time of the 2006 Trials commentary, only a
handful of papers had previously called for data sharing.
There was a paper published 10 years previously in the
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BMJ, the title of which, in a case of inadvertent plagiar-
ism, the commentary had mirrored [2]. Kirwan’s review
of data-sharing attitudes [3] had been cited in the com-
mentary and, of course, one could go all the way back to
the first issue of Biometrika, in which Galton called for
publication of data alongside the primary analyses [4]. It
might also be noted that at the time of the commentary,
no major institution had called for clinical trial data
sharing to be a matter of course.
Main text
Today, ten years on from publication of the Trials com-
mentary, the situation could not be more different: nu-
merous organizations now recommend or require raw
data to be made available, and the literature is replete with
papers covering an enormously wide variety of topics on
data sharing. In terms of recommendations, clinical trial
data sharing has been the subject of a report from the
Institute of Medicine, [5, 6] which recommends, among
other things, that funders should require trialists to share
data and provide appropriate support to do so. Funders
have certainly shown interest, with a group of 17 funders
led by the Wellcome Trust publishing a “statement of pur-
pose” on data sharing, including a set of principles [7].
Some funders have gone beyond principles: the National
Health, Lung and Blood Institute [8], for instance, has
developed specific data-sharing practices and a data re-
pository currently including over half a million patients
from over 100 trials and observational studies. In a recent,
dramatic development, the International Committee of
Medical Journal Editors has recommended that as a “con-
dition of … publication” of a trial report, journals will “re-
quire authors to share with others the deidentified
individual-patient data no later than 6 months after publi-
cation” [9]. If fully enacted, this recommendation would
transform the landscape of clinical trial data sharing. The
BMJ has already taken the lead, with a policy that now
requires data sharing “on request” for all trials [10]. Some
pharmaceutical groups are following suit, with Roche stat-
ing that they will provide individual patient data from clin-
ical trials in response to requests with “good scientific
merit” [11]. Project Data Sphere [12] is an industry-led ini-
tiative to provide a software platform for clinical trial data
sharing, and initiatives by GSK and Medtronic to share
clinical trial data have received wide praise [10].
Alongside these initiatives and recommendations, a sub-
stantial literature has been published that investigates data
sharing as a research topic. We have seen papers develop-
ing data standards for clinical trials in narrow fields (for in-
stance, polycystic kidney disease [13] and spinal cord injury
[14]); technical papers on deidentification [15]; numerous
surveys about the practice of or attitudes to data sharing
[16–21]; discussion of ethical issues [22] (including those
pertaining to highly localized issues in countries such as
South Africa [23] or Vietnam [24]); and practical guidance
on how to share data [25, 26].
All that said, the war is far from won: attitudes have
shifted dramatically, tectonically, but we are yet to see clin-
ical trial data sharing become an unquestioned norm,
where, say, a researcher can readily download a data set
from a trial almost as easily as they can now download the
trial publication. And there are still battles to be fought: the
Pharmaceutical Research and Manufacturers of America,
for instance, claims to be “firmly committed to enhancing
public health” but current guidelines on communication of
trial results [27] speak of making clinical trial data access-
ible only to investigators.
Conclusions
I draw three conclusions from my experiences in promot-
ing clinical trial data sharing. First, we are blessed to be
working in a discipline in which reason matters, and where
individuals will change their attitudes when presented with
sound arguments. Second, dramatic cultural change is
indeed possible within a short period of time, if the cause is
just. Third, changing attitudes is not enough. In the “states
of change” model describing how, say, a smoker quits
smoking cigarettes, “contemplation” and “preparation” need
to be followed by “action” and “maintenance.” The 2006
commentary ended: “Let’s make sharing of raw data a com-
monplace, natural part of the clinical trials process, in the
same way that we view obtaining ethical approval or publi-
cation of the trial results.” Our job over the next decades
will be to make sure, first, that this does indeed happen
and, second, that it stays that way.
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